Regulation of MDR1 gene expression in multidrug-resistant cancer cells is independent from YB-1

Related Experiment Video

Updated: Jul 15, 2026

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
07:56

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

Alexander Kaszubiak1, Annette Kupstat, Ursula Müller

  • 1Charité Campus Mitte, Institute of Pathology, Charitéplatz 1, D-10117 Berlin, Germany.

Biochemical and Biophysical Research Communications
|April 10, 2007
PubMed

Insights

This study investigated Y-box binding protein 1 (YB-1) as a regulator of multidrug resistance (MDR) in cancer. Results show YB-1 does not influence MDR1 gene expression or drug resistance in MDR cancer cells.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetics

Background:

  • Multidrug resistance (MDR) in cancer, mediated by the MDR1 gene and P-glycoprotein, significantly hinders chemotherapy effectiveness.
  • Y-box binding protein 1 (YB-1) was hypothesized to be a key regulator of MDR1 gene expression and a contributor to drug resistance in tumor cells.

Purpose of the Study:

  • To investigate the role of YB-1 in regulating the MDR1 gene and influencing the drug-resistant phenotype in MDR cancer cells.
  • To assess the efficacy of gene-silencing strategies targeting YB-1.

Main Methods:

  • Designed and utilized small interfering RNAs (siRNAs) for transient YB-1 gene silencing.
  • Developed tetracycline-inducible short hairpin RNA (shRNA) expression vectors for stable YB-1 inhibition in MDR and drug-sensitive cell lines.
  • Quantified YB-1 mRNA and protein expression levels following gene silencing.
  • Assessed MDR1 gene expression and drug resistance phenotypes.

Main Results:

  • Both transient siRNA and stable shRNA approaches successfully inhibited YB-1 mRNA and protein expression in cancer cells upon tetracycline induction.
  • Complete inhibition of YB-1 did not lead to any modulation of MDR1 gene expression.
  • The drug-resistant phenotype of the MDR cancer cells remained unchanged despite YB-1 silencing.

Conclusions:

  • The developed siRNAs and shRNAs are effective laboratory tools for YB-1 gene silencing.
  • YB-1 is not involved in the regulation of the MDR1 gene in the studied MDR cancer cell lines.
  • YB-1 does not play a role in the development or maintenance of the drug-resistant phenotype in these MDR cancer cells.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...